Skip Navigation


Rheumatology Advance Access originally published online on May 18, 2005
Rheumatology 2005 44(8):975-982; doi:10.1093/rheumatology/keh688
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
44/8/975    most recent
keh688v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Riemekasten, G.
Right arrow Articles by Hahn, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riemekasten, G.
Right arrow Articles by Hahn, B. H.
Related Collections
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org


REVIEW

Key autoantigens in SLE

G. Riemekasten and B. H. Hahn1

Charité University Hospital, Rheumatology and Clinical Immunology, Berlin, Germany and 1 University of California Los Angeles, Rheumatology, Los Angeles, California, USA.

Correspondence to: G. Riemekasten. E-mail: gabriela.riemekasten@charite.de

The first 150 words of the full text of this article appear below.


    Introduction
 
Murine and human systemic lupus erythematosus (SLE, lupus) is characterized by the appearance of autoantibodies directed to nuclear and cell membrane phospholipid components. Some functionally related nucleic acid-containing macromolecules such as chromatin or ribonucleoprotein particles are specifically targeted both by autoantibodies and T cells involved in lupus pathogenesis. In the last decade, the identification of target structures has strongly improved diagnostic tools. Furthermore, characterization of autoantigens has provided insight into pathogenic mechanisms to understand why these autoantigens are recognized in SLE. However, the recognition of autoantigens and a stable immune response towards these specificities requires the coincidence of several events (such as environmental triggers in the external world) plus abnormalities in genetically susceptible organisms that modify normal immune responses. Furthermore, the persistence of the autoantibody response in lupus long after the initial trigger suggests that endogenous autoantigens (from the internal world) are important in sustaining the ongoing immune response. Once . . . [Full Text of this Article]


    The external world—infections and autoantigens (molecular mimicry)
 

    Role of innate immune system in SLE—new insights from the discovery of Toll-like receptors
 

    The key autoantigens as targets of the immune response in lupus
 
Nucleosomes as targets of the autoantibody immune response
Sm autoantigens of the small nuclear ribonucleoprotein

    Apoptosis and detective clearance and lupus autoantigens
 

    T-cell help and expansion of the antiself response by spreading
 

    Future perspectives
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
A. Sharabi, D. Luger, H. Ben-David, M. Dayan, H. Zinger, and E. Mozes
The Role of Apoptosis in the Ameliorating Effects of a CDR1-Based Peptide on Lupus Manifestations in a Mouse Model
J. Immunol., October 15, 2007; 179(8): 4979 - 4987.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
M Ishii, Y Muramoto, H Kosaka, S Ohshima, T Mima, Y Katada, S Hirohata, and Y Saeki
A serological switching from anti-dsDNA to anti-Sm antibodies coincided with severe clinical manifestations of systemic lupus erythematosus (hemophagocytosis, profundus and psychosis)
Lupus, January 1, 2007; 16(1): 67 - 69.
[PDF]